Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of a Phase III randomized trial to compare the benefit of gefitinib versus pemetrexed/carboplatin for epidermal growth factor receptor-mutated non-small cell lung cancer

Background:> In an open-label, Phase III randomized study, gefitinib was found to be superior to pemetrexed-platinum in terms of progression-free survival in patients with epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer. In this analysis, we have assessed the efficacy o...

Full description

Bibliographic Details
Main Authors: Vijay Patil, Vanita Noronha, Amit Joshi, Anuradha Chougule, Atanu Bhattacharjee, Alok Goel, Vikas Talreja, Nandini Menon, Anant Ramaswamy, Ashay Karpe, Nikhil Pande, Arun Chandrasekharan, Abhishek Mahajan, Amit Janu, Nilendu Purandare, Kumar Prabhash
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Cancer Research, Statistics, and Treatment
Subjects:
carboplatin
epidermal growth factor receptor
epidermal growth factor receptor mutation
gefitinib
non-small cell lung cancer
pemetrexed
quality-adjusted time without symptoms or toxicity
Online Access:http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=21;epage=27;aulast=

Internet

http://www.crstonline.com/article.asp?issn=2590-3233;year=2019;volume=2;issue=1;spage=21;epage=27;aulast=

Similar Items